MedTrace Logo

The Effect of Phonophoresis in Subacromial Impingement Syndrome.

NCT04676919 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-07-28

No results posted yet for this study

Summary

Subacromial impingement syndrome (SIS) is a dysfunction caused by an impingement of the rotator cuff tendon between the head of the humerus and the acromion as a result of changes in the subacromial space. The patients' symptoms, such as pain, limited joint mobility and reduced strength, may lead to a diagnosis of SIS. The conservative treatment of individuals with SIS is includes analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), steroid injections and physiotherapy. Ultrasound therapy is one of the common physiotherapy applications for SIS, but its effectiveness is controversial. Phonophoresis is a combination of ultrasound therapy and medical therapy. In phonophoresis, a medicine in gel form is used as a transmitter with ultrasound instead of the aquatic conductor gel. It was hypothesized that ultrasound waves favoring the penetration of an anti-inflammatory drug would lead to an improved response to the treatment of SIS. However, the effectiveness of ultrasound modes (pulsed or continuous) can be used in phonophoresis is debatable. The purpose of this study is to determine the effect of ultrasound therapy, pulsed mode ultrasound and continuous mode ultrasound phonophoresis in patients with SIS.

Conditions

  • Subacromial Impingement Syndrome

Interventions

DEVICE

phonophoresis therapy with pulsed mode ultrasound

phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks

DEVICE

phonophoresis therapy with continuous mode ultrasound

phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks

DEVICE

sham ultrasound

sham ultrasound therapy, five days a week for three weeks

Sponsors & Collaborators

  • Cukurova University

    lead OTHER

Principal Investigators

  • Bayram Kelle, Assoc. Prof. · Cukurova University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-01-15
Completion
2021-01-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676919 on ClinicalTrials.gov